HERON THERAPEUTICS, INC. /DE/
About HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$20.2M
- Total assets
- $255.9M
- Market cap
- $80.9M
- Gross margin
- 73.3%
- Operating margin
- -1.6%
- Net margin
- -13.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $154.9M
- Cost of revenue
- $41.3M
- Gross profit
- $113.6M
- Operating expenses
- $116.1M
- Operating income
- -$2.5M
- Income tax
- $0
- Net income
- -$20.2M
- EPS (basic)
- $-0.12
- EPS (diluted)
- $-0.12
Balance sheet
- Total assets
- $255.9M
- Current assets
- $238.1M
- Total liabilities
- $241.5M
- Current liabilities
- $96.1M
- Shareholders’ equity
- $14.3M
Cash flow
- Operating cash flow
- -$27.6M
- Investing cash flow
- $16.0M
- Financing cash flow
- $14.4M
- Net cash flow
- $2.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $80.9M
- EPS (diluted)
- $-0.12
- Shares outstanding
- 179.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 27, 1987
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $20.2M.
- Revenue grew 79% from FY2021 to FY2025.
- Gross margin of 73.3%, net margin -13.0%.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HERON THERAPEUTICS, INC. /DE/.
Write a review
News about HERON THERAPEUTICS, INC. /DE/
News & sentiment via Polygon.io
